Schizophrenia

Mindful cognitive enhancement training for psychosis: a pilot study.

Tabak NT, Granholm E. Mindful cognitive enhancement training for psychosis: a pilot study. Schizophr Res. 2014;157(1-3):312-3. DOI: 10.1016/j.schres.2014.06.002. PubMed PMID: 24968738.

Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort.

Canetta S, Sourander A, Surcel H-M, Hinkka-Yli-Salomäki S, Leiviskä J, Kellendonk C, et al.. Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort. Am J Psychiatry. 2014;171(9):960-8. DOI: 10.1176/appi.ajp.2014.13121579. PubMed PMID: 24969261.

Abnormalities in white matter connections between orbitofrontal cortex and anterior cingulate cortex and their associations with negative symptoms in schizophrenia: a DTI study.

Ohtani T, Bouix S, Hosokawa T, Saito Y, Eckbo R, Ballinger T, et al. Abnormalities in white matter connections between orbitofrontal cortex and anterior cingulate cortex and their associations with negative symptoms in schizophrenia: a DTI study. Schizophr Res. 2014;157(1-3):190-7. DOI: 10.1016/j.schres.2014.05.016. PubMed PMID: 24962436.

Deviant dynamics of EEG resting state pattern in 22q11.2 deletion syndrome adolescents: A vulnerability marker of schizophrenia?

Tomescu MI, Rihs TA, Becker R, Britz J, Custo A, Grouiller F, et al. Deviant dynamics of EEG resting state pattern in 22q11.2 deletion syndrome adolescents: A vulnerability marker of schizophrenia?. Schizophr Res. 2014;157(1-3):175-81. DOI: 10.1016/j.schres.2014.05.036. PubMed PMID: 24962438.

Amusia and cognitive deficits in schizophrenia: is there a relationship?

Wen Y, Nie X, Wu D, Liu H, Zhang P, Lu X. Amusia and cognitive deficits in schizophrenia: is there a relationship?. Schizophr Res. 2014;157(1-3):60-2. DOI: 10.1016/j.schres.2014.05.029. PubMed PMID: 24957355.

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.

Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophrenia Res. 2009;107(1):22-9. DOI: 10.1016/j.schres.2008.09.031. PubMed PMID: 18993031.

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Res. 2005;80(1):45-53. DOI: 10.1016/j.schres.2005.08.010. PubMed PMID: 16198088.

Antipsychotic treatment response in schizophrenia.

Gardner KN, Bostwick JR. Antipsychotic treatment response in schizophrenia. Am J Health Syst Pharm. 2012;69(21):1872-9. DOI: 10.2146/ajhp110559. PubMed PMID: 23111671.

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013;11(2):95-106. DOI: 10.1007/s40258-013-0016-2. PubMed PMID: 23494934.

Using ECT in schizophrenia: a review from a clinical perspective.

Zervas IM, Theleritis C, Soldatos CR. Using ECT in schizophrenia: a review from a clinical perspective. World J Biol Psychiatry. 2012;13(2):96-105. DOI: 10.3109/15622975.2011.564653. PubMed PMID: 21486108.